Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Nagai

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Bioscience, Biotechnology, and Biochemistry|October 26, 2005
Substrate shape preference of Escherichia coli ribonuclease P ribozyme and holo enzyme using bottom-half part-shifting variants of pre-tRNATerumichi Tanaka, Yasuhiro Nagai, Yo Kikuchi
Frontiers in Immunology|November 29, 2023
Editorial: Updates on toll-like receptors in cancer immunity and immunotherapyBettina Hoden, Yasuhiro Nagai, Laura Schuettpelz, et al.
Nucleic Acids Research. Supplement (2001)|September 27, 2003
Recognition of tRNA bottom half by bacterial ribonuclease PYasuhiro Nagai, Tomoaki Ando, Terumichi Tanaka, et al.
Journal of Biochemistry|November 15, 2008
Analysis on substrate specificity of Escherichia coli ribonuclease P using shape variants of pre-tRNA: proposal of subsites model for substrate shape recognitionSatoshi Suwa, Yasuhiro Nagai, Akihiro Fujimoto, et al.
Journal of Leukocyte Biology|December 2, 2011
Stimulation of Ly-6G on neutrophils in LPS-primed mice induces platelet-activating factor (PAF)-mediated anaphylaxis-like shockYukinori Tanaka, Yasuhiro Nagai, Toshinobu Kuroishi, et al.
Nucleic Acids Symposium Series (2004)|September 9, 2008
Subsites for substrate recognition by bacterial ribonuclease PAkihiro Fujimoto, Satoshi Suwa, Yasuhiro Nagai, et al.
Frontiers in Immunology|April 25, 2020
PRMT5 Is Required for T Cell Survival and Proliferation by Maintaining Cytokine SignalingYukinori Tanaka, Yasuhiro Nagai, Mariko Okumura, et al.
Experimental and Molecular Pathology|May 7, 2013
Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancersTaofeng Du, Yasuhiro Nagai, Yan Xiao, et al.
Immunology|February 7, 2012
Histamine reduces susceptibility to natural killer cells via down-regulation of NKG2D ligands on human monocytic leukaemia THP-1 cellsYasuhiro Nagai, Yukinori Tanaka, Toshinobu Kuroishi, et al.
Frontiers in Oncology|September 30, 2024
DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironmentYosuke Ota, Ryosaku Inagaki, Kentaro Sumida, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Bioscience, Biotechnology, and Biochemistry|October 26, 2005
Substrate shape preference of Escherichia coli ribonuclease P ribozyme and holo enzyme using bottom-half part-shifting variants of pre-tRNATerumichi Tanaka, Yasuhiro Nagai, Yo Kikuchi
Frontiers in Immunology|November 29, 2023
Editorial: Updates on toll-like receptors in cancer immunity and immunotherapyBettina Hoden, Yasuhiro Nagai, Laura Schuettpelz, et al.
Nucleic Acids Research. Supplement (2001)|September 27, 2003
Recognition of tRNA bottom half by bacterial ribonuclease PYasuhiro Nagai, Tomoaki Ando, Terumichi Tanaka, et al.
Journal of Biochemistry|November 15, 2008
Analysis on substrate specificity of Escherichia coli ribonuclease P using shape variants of pre-tRNA: proposal of subsites model for substrate shape recognitionSatoshi Suwa, Yasuhiro Nagai, Akihiro Fujimoto, et al.
Journal of Leukocyte Biology|December 2, 2011
Stimulation of Ly-6G on neutrophils in LPS-primed mice induces platelet-activating factor (PAF)-mediated anaphylaxis-like shockYukinori Tanaka, Yasuhiro Nagai, Toshinobu Kuroishi, et al.
Nucleic Acids Symposium Series (2004)|September 9, 2008
Subsites for substrate recognition by bacterial ribonuclease PAkihiro Fujimoto, Satoshi Suwa, Yasuhiro Nagai, et al.
Frontiers in Immunology|April 25, 2020
PRMT5 Is Required for T Cell Survival and Proliferation by Maintaining Cytokine SignalingYukinori Tanaka, Yasuhiro Nagai, Mariko Okumura, et al.
Experimental and Molecular Pathology|May 7, 2013
Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancersTaofeng Du, Yasuhiro Nagai, Yan Xiao, et al.
Immunology|February 7, 2012
Histamine reduces susceptibility to natural killer cells via down-regulation of NKG2D ligands on human monocytic leukaemia THP-1 cellsYasuhiro Nagai, Yukinori Tanaka, Toshinobu Kuroishi, et al.
Frontiers in Oncology|September 30, 2024
DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironmentYosuke Ota, Ryosaku Inagaki, Kentaro Sumida, et al.
Pageof 4